Scientific deep-dive

Orforglipron (Foundayo) Side Effects: Label Trial Rates

What the FDA Foundayo label and the ATTAIN-1 phase 3 trial actually report for orforglipron side effects — the GI rates, the boxed MTC warning, the pancreatitis and gallbladder signal, and how the oral pill compares to injectable Wegovy and Zepbound.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
11 min read·8 citations

The most common Foundayo (orforglipron) side effects are nausea, diarrhea, vomiting, constipation, and dyspepsia (indigestion) — all gastrointestinal. The label reports GI adverse reactions in 60%, 68%, and 69% of patients on 5.5, 9, and 17.2 mg vs 37% on placebo, and nausea, vomiting, and diarrhea were more common during dose escalation and decreased over time[1]. Foundayo carries the same boxed warning for medullary thyroid carcinoma as every other FDA-approved GLP-1 receptor agonist, and the same warnings for pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycemia in combination with insulin or sulfonylureas, allergic reactions, and pregnancy[1]. This article walks through what the FDA Foundayo label and the ATTAIN-1 phase 3 trial actually report, how those rates compare to injectable Wegovy and Zepbound, and the practical questions patients keep searching for.

Find your week: our side-effect timeline tool shows when each side effect peaks and resolves, by drug and week, with every cell anchored to a primary source (FDA label or pivotal trial publication).

Quick answer

The most common Foundayo (orforglipron) side effects are nausea, diarrhea, vomiting, constipation, and dyspepsia (indigestion) — all GI, in 60-69% of patients across the 5.5, 9, and 17.2 mg doses vs 37% on placebo, more common during dose escalation and decreasing over time. Foundayo also carries the same boxed warning for medullary thyroid carcinoma and the same pancreatitis, gallbladder, hypoglycemia (in combination), kidney, and pregnancy warnings as every other FDA-approved GLP-1.

Most common side effects (ATTAIN program and FDA label)

Foundayo's approval was anchored on ATTAIN-1, a 72-week, randomized, double-blind, placebo-controlled phase 3 trial in adults with obesity or overweight without type 2 diabetes[2]. The Eli Lilly approval press release for Foundayo identifies the most commonly reported adverse events in the ATTAIN program as the standard GLP-1 gastrointestinal cluster — nausea, constipation, diarrhea, vomiting, abdominal pain, indigestion, belching, and heartburn — plus headache, abdominal distension, fatigue, gas, and hair loss[2].

The exact percentage point rates patients should consult are in Section 6 (Adverse Reactions) of the FDA Foundayo Prescribing Information[1]. The qualitative pattern is identical to what semaglutide and tirzepatide produce in their respective trials: GI events are more common during dose escalation and decrease over time (the Foundayo dosing schedule lists each step). The FDA label is the source of truth — when in doubt, read Section 6 or ask your prescriber.

Side effect categoryFoundayo 17.2 mg vs placebo (FDA label)Class context
Nausea35% vs 10%44% vs 16% with Wegovy 2.4 mg in its label's adult weight-reduction trials[3]
Diarrhea25% vs 11%Common across all GLP-1 trials[3]
Vomiting24% vs 4%Common across all GLP-1 trials[3]
Constipation24% vs 9%Common across all GLP-1 trials[3]
Dyspepsia13% vs 4%Class effect across all GLP-1 agonists[3]
Abdominal pain14% vs 7%Reported across the GLP-1 class[2]

Per Section 6 (Adverse Reactions) of the FDA Foundayo prescribing information, the most common GI adverse-event rates at the 17.2 mg dose vs placebo over 72 weeks were nausea 35% vs 10%, diarrhea 25% vs 11%, vomiting 24% vs 4%, constipation 24% vs 9%, and dyspepsia 13% vs 4% [1]. At 5.5 mg, nausea was 26% and vomiting 13%, while diarrhea (21%) and dyspepsia (12%) were closer to the top-dose figures. The qualitative pattern — GI dominant, more common during escalation, decreasing over time — is consistent across every FDA-approved GLP-1 receptor agonist[3][4].

Magnitude comparison

GI adverse-event rates at the 17.2 mg Foundayo dose vs placebo in the label's pool of Trials 1 and 2 (ATTAIN-1 and ATTAIN-2, 72 weeks), per the FDA Foundayo prescribing information Section 6.[1]

  • Nausea — Foundayo 17.2 mg35 %
  • Nausea — placebo10 %
  • Diarrhea — Foundayo 17.2 mg25 %
  • Diarrhea — placebo11 %
  • Vomiting — Foundayo 17.2 mg24 %
  • Vomiting — placebo4 %
  • Constipation — Foundayo 17.2 mg24 %
  • Constipation — placebo9 %
  • Dyspepsia — Foundayo 17.2 mg13 %
  • Dyspepsia — placebo4 %
GI adverse-event rates at the 17.2 mg Foundayo dose vs placebo in the label's pool of Trials 1 and 2 (ATTAIN-1 and ATTAIN-2, 72 weeks), per the FDA Foundayo prescribing information Section 6.

GI side effects in detail

The four GI events that drive most Foundayo discontinuation in the early weeks are nausea, vomiting, diarrhea, and constipation. They share a mechanism: GLP-1 receptor activation slows gastric emptying, which is exactly the appetite suppression mechanism patients are paying for. The same slowed-emptying signal that makes you feel full after a few bites is what makes a too-large meal feel uncomfortable for hours afterward.

A common patient assumption is that an oral GLP-1 will be easier on the stomach than an injection. The trial data does not support that assumption. Foundayo is taken into the bloodstream and reaches the same GLP-1 receptors throughout the body — including the receptors on the GI tract — that injectable semaglutide and tirzepatide activate. The route of administration changes nothing about the downstream pharmacology[2]. Foundayo's GI tolerability profile is broadly comparable to injectable semaglutide at comparable receptor activation, not better.

The single biggest tolerability lever is titration speed. The labeled Foundayo titration moves from 0.8 mg up to a 17.2 mg maximum, with at least 30 days on each step[1]. Patients who escalate too fast — chasing weight loss — typically pay for it with a week of GI symptoms after each step. Patients who stay on a step longer when they need to typically tolerate the next dose much better. See our Foundayo dosing guide for the full titration table.

Boxed warning: medullary thyroid carcinoma

Foundayo carries the same boxed warning as every other FDA-approved GLP-1 receptor agonist — Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Trulicity, Victoza, Rybelsus — for thyroid C-cell tumors, including medullary thyroid carcinoma (MTC)[1][3][4]. Foundayo is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)[1].

The boxed warning is based on rodent data, not human data. In the original carcinogenicity studies submitted for liraglutide and subsequent GLP-1 agonists, rats and mice given long-term high-dose GLP-1 exposure developed thyroid C-cell tumors. The relevance of that signal to humans is uncertain — humans have far fewer C-cells than rodents and the receptor density and signaling differ — and large pharmacovigilance studies have not consistently replicated a thyroid cancer signal in humans on GLP-1 agonists. A 2023 nested case-control study in the French national health database (Bezin et al., Diabetes Care) reported an association between cumulative GLP-1 use and thyroid cancer that has been heavily debated for residual confounding[5]. The current consensus is that the absolute risk in humans is very low if it exists at all, but the FDA has chosen to maintain the boxed warning across the class until cleaner long-term human data are available.

For our full review of the GLP-1 thyroid cancer evidence, including the Bezin paper, the Spanish cohort, and the more reassuring SELECT post-hoc data, see Does GLP-1 cause cancer? The MTC and thyroid evidence.

Less common but serious adverse events

The Foundayo FDA label includes the same Section 5 (Warnings and Precautions) safety topics as the rest of the GLP-1 class[1]:

  • Pancreatitis. Acute pancreatitis has been reported across the GLP-1 class in postmarketing surveillance. Foundayo should be discontinued if pancreatitis is suspected. Patients with a personal history of pancreatitis should discuss the risk-benefit with their prescriber[1].
  • Gallbladder disease (cholelithiasis, cholecystitis). GLP-1 agonists are associated with an increased rate of gallbladder events, particularly in the context of rapid weight loss[3]. The Foundayo label warns for the same signal.
  • Acute kidney injury. Severe GI side effects can cause dehydration, which in turn can cause acute kidney injury or worsen pre-existing chronic kidney disease. Patients should hydrate aggressively, especially during titration[1].
  • Hypoglycemia. Foundayo alone does not typically cause hypoglycemia in non-diabetic patients because GLP-1 only stimulates insulin in the presence of elevated glucose. Risk increases substantially when Foundayo is combined with insulin or a sulfonylurea[1], which is why diabetic patients on those drugs need a dose reduction at the start of GLP-1 therapy.
  • Hypersensitivity (allergic) reactions. Serious allergic reactions including anaphylaxis and angioedema have been reported across the GLP-1 class. Discontinue and seek emergency care for any signs of a severe allergic reaction[1].
  • Mood changes. The Foundayo label carries no suicidality warning, and none of the GLP-1 weight-management labels do any more: the FDA reviewed the class in 2024, found no causal link, then pooled 91 placebo-controlled trials in 107,910 patients and had the precaution struck from the Wegovy, Zepbound, and Saxenda labels in February 2026[8]. Tell your prescriber about new or worsening depression or unusual mood changes anyway — the FDA still asks patients to, and it matters most if you have a history of mood disorders.
  • Pulmonary aspiration during anesthesia. Because GLP-1 agonists slow gastric emptying, patients on Foundayo undergoing elective surgery or any procedure requiring sedation should tell their care team they take it; the label notes rare postmarketing reports of pulmonary aspiration under general anesthesia or deep sedation[1]. The 2024 multisociety guidance, which the American Society of Anesthesiologists co-signed, says GLP-1 drugs may be continued in patients without elevated risk of delayed gastric emptying, with a liquid diet for at least 24 hours or withholding considered for those at higher risk[6].

Pregnancy and fertility

Pregnancy is not among Foundayo's contraindications. What the label does say is that the drug may cause fetal harm and that treatment stops when a pregnancy is recognized[7], based on animal reproduction findings. It sets no pre-conception window at all — the phrases “2 months” and “planned pregnancy” appear nowhere in it. That two-month rule belongs to the semaglutide labels, Wegovy and Ozempic, and comes from semaglutide's roughly one-week half-life[3]. Orforglipron clears far faster, with an elimination half-life of about 29 to 49 hours[7], so anyone planning a pregnancy should set the stop date with their prescriber rather than borrow semaglutide's number.

A separate consideration for women of reproductive age: Foundayo's prescribing information includes a specific oral contraceptive interaction. Per Section 7.1 of the Foundayo PI, women on oral contraceptives should add a barrier method (or switch to a non-oral hormonal method, an IUD, or an implant) for 30 days after starting Foundayo and 30 days after each dose increase[1]. For the broader fertility and pregnancy picture across the GLP-1 class, see GLP-1s, pregnancy, PCOS, and women's reproductive health.

How Foundayo side effects compare to injectable GLP-1s

The honest answer: rates look broadly similar across the class. The Wegovy (semaglutide 2.4 mg) label reports nausea in 44% of adults in its weight-reduction trials, diarrhea in 30%, vomiting in 24%, and constipation in 24%[3]. Zepbound (tirzepatide) reported similar rates in SURMOUNT-1[4]. Foundayo's ATTAIN program identifies the same GI cluster as the most common adverse events[2], and the FDA Foundayo label includes the same warnings as Wegovy and Zepbound[1].

The fair statement is that oral delivery does not meaningfully change the GI tolerability profile of a GLP-1 agonist. The differences between Foundayo and the injectables are:

  • Daily vs weekly dosing. Foundayo is a once-daily pill; Wegovy, Ozempic, Zepbound, and Mounjaro are once-weekly injections. A daily oral dose creates a smoother concentration curve with less peak-to-trough swing, which some patients tolerate better.
  • No injection site reactions. Foundayo eliminates the redness, itching, and lump at the injection site that some injectable patients experience.
  • Effect size. Foundayo's 17.2 mg labeled-dose efficacy (~11.1% mean weight loss in non-diabetic adults) sits below injectable semaglutide (~14.9% in STEP-1) and well below tirzepatide (~20.9% in SURMOUNT-1). The trade-off is convenience vs maximum weight loss.

For the side-by-side trial-arm comparison and price breakdown, see our Foundayo vs Wegovy vs Zepbound comparison and the broader GLP-1 side effects investigation.

Managing side effects

Most Foundayo GI side effects are manageable with simple practical changes, especially during the first weeks on a new dose. The four highest-leverage interventions:

  1. Slow titration. The single biggest lever. If a step makes you feel terrible for more than a few days, ask your prescriber whether you can stay on the previous dose for an extra 4 weeks before trying again. The labeled schedule is a maximum, not a minimum.
  2. Smaller, more frequent meals. Slowed gastric emptying makes large meals feel uncomfortable for hours. Stop eating at the first sign of fullness. Most patients find that 4-5 small meals per day are tolerated far better than 2-3 normal-sized ones.
  3. Hydration. Aim for at least 64 oz of non-caloric fluid daily, more if you have any vomiting or diarrhea. Dehydration is the mechanism behind the kidney injury warning on the Foundayo label[1].
  4. Antiemetics for severe nausea. Prescribers can prescribe ondansetron (Zofran) or prochlorperazine for short courses if titration adjustment is not enough. Do not self-medicate without checking with your prescriber.

For a full practical playbook on GLP-1 nausea management across the class, see GLP-1 nausea management practical guide.

When to call your doctor

Red flags — call your prescriber or seek care

  • Severe persistent vomiting that prevents keeping fluids down for more than 24 hours, or any signs of dehydration (dark urine, dizziness, rapid heart rate).
  • Severe abdominal pain, especially upper abdominal pain that radiates to the back — possible pancreatitis. Stop Foundayo and seek evaluation.
  • Right upper quadrant pain, fever, or jaundice — possible gallbladder event.
  • Neck swelling, hoarseness, trouble swallowing, or shortness of breath — discuss with your prescriber given the boxed thyroid warning.
  • Hives, facial or tongue swelling, trouble breathing — possible severe allergic reaction. Seek emergency care.
  • New or worsening depression, suicidal thoughts, or unusual mood changes — contact your prescriber.
  • Symptoms of low blood sugar (shaking, sweating, confusion) if you are on Foundayo plus insulin or a sulfonylurea — contact your prescriber for a dose reassessment.

Bottom line

  • The most common Foundayo (orforglipron) side effects are GI: nausea, diarrhea, vomiting, constipation, and dyspepsia. They are more common during dose escalation and decrease over time[1][2].
  • Foundayo carries the same boxed warning for medullary thyroid carcinoma as the rest of the GLP-1 class, based on rodent data. Contraindicated with personal or family history of MTC or MEN 2[1].
  • The same Section 5 warnings as Wegovy and Zepbound: pancreatitis, gallbladder disease, kidney injury, hypoglycemia (in combination with insulin or sulfonylureas), allergic reactions, anesthesia aspiration risk, and a fetal-harm warning with an instruction to stop once a pregnancy is recognized[1][6][7].
  • Oral delivery does not meaningfully change GI tolerability versus injectable GLP-1s. The differences are dosing frequency, no injection site reactions, and a somewhat smaller effect size at the labeled top dose.
  • The biggest tolerability lever is titration speed. Stay on a step longer if you need to.

Adverse event rates (nausea 35% vs 10%, diarrhea 25% vs 11%, vomiting 24% vs 4%, constipation 24% vs 9%, dyspepsia 13% vs 4%, abdominal pain 14% vs 7%) are quoted from Section 6 (Adverse Reactions) of the FDA Foundayo (orforglipron) Prescribing Information at the 17.2 mg dose vs placebo in the label's pool of two 72-week placebo-controlled trials (ATTAIN-1 and ATTAIN-2). Rates differ at lower doses than these top-dose figures. Always verify with your prescribing clinician and consult the most current FDA prescribing information before making any decisions about a prescription medication.

Further reading

Frequently Asked Questions

No. The FDA Foundayo label and the ATTAIN-1 trial show the same GI side effect profile as injectable semaglutide — nausea, diarrhea, vomiting, constipation, and dyspepsia. Rates are broadly similar across the GLP-1 class because the mechanism is the same. Oral delivery does not make the GI effects worse.
Most GI side effects appear in the first days after starting Foundayo or after a dose increase, and often ease as the body adapts. Persistent or severe symptoms should be reviewed with the prescribing clinician — sometimes the answer is to slow titration or stay an extra cycle on the current dose.
Stopping any GLP-1 typically causes some weight regain because the appetite signal returns. Long-term post-discontinuation data on orforglipron specifically has not been published yet, but the pattern documented for injectable semaglutide in STEP-1 and STEP-4 is that most patients regain a substantial fraction of lost weight within a year after stopping. Plan the off-ramp with a clinician.
The Foundayo label says to take it once daily, with or without food, so you can take it with a meal if that sits better. The label does not say that food reduces nausea. To reduce nausea, focus on the rest of the day: eat smaller meals, avoid greasy or very rich foods, stay hydrated, and stop eating at the first sign of fullness. Your prescriber can also slow the titration schedule.
The Foundayo FDA label carries the same boxed warning for medullary thyroid carcinoma and the same warnings for pancreatitis, gallbladder disease, kidney injury, hypoglycemia in combination with insulin or sulfonylureas, allergic reactions, and the same fetal-harm warning with an instruction to stop once a pregnancy is recognized, as Wegovy, Ozempic, and Zepbound. The safety profile is broadly the same across the class.
Mild to moderate GI side effects in the first weeks are expected and usually do not require stopping — they typically resolve as the body adapts. Stop and call the prescriber for severe persistent vomiting, severe abdominal pain (possible pancreatitis), neck swelling or trouble swallowing (possible thyroid issue), signs of an allergic reaction, or signs of dehydration.
The FDA Foundayo prescribing information lists two absolute contraindications: a personal or family history of medullary thyroid carcinoma (MTC), and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) - both based on the class-wide boxed warning for thyroid C-cell tumors observed in rodent carcinogenicity studies. Pregnancy is not one of them. The label warns that Foundayo may cause fetal harm, based on animal reproduction studies, and says to discontinue once a pregnancy is recognized; it sets no pre-conception window, so anyone planning a pregnancy should agree a stop date with the prescriber. Several additional groups require prescriber caution rather than automatic exclusion: patients with a personal history of pancreatitis, those on insulin or sulfonylureas (who need dose reductions to prevent hypoglycemia, since Foundayo's glucose-lowering effect adds to theirs), and women on oral contraceptives (who need to add a barrier method for 30 days after starting Foundayo and after each dose increase, due to the drug's effect on oral contraceptive absorption). Patients with severe gastroparesis or other serious GI motility disorders are also a prescriber-level concern, since further slowing of gastric emptying could worsen those conditions.

References

  1. 1.U.S. Food and Drug Administration. FOUNDAYO (orforglipron) tablets: US Prescribing Information (FDA-approved April 1, 2026). Includes boxed warning for thyroid C-cell tumors, warnings and precautions, and adverse reactions sections. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  2. 2.Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss — investor press release with ATTAIN-1 phase 3 trial efficacy and safety summary. Eli Lilly Investor Relations. 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
  3. 3.U.S. Food and Drug Administration. WEGOVY (semaglutide) injection — US Prescribing Information. Boxed warning for thyroid C-cell tumors and full adverse reactions table from the STEP program. FDA Approved Labeling. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  4. 4.U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection — US Prescribing Information. Boxed warning, warnings and precautions, and SURMOUNT program adverse reactions data. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  5. 5.Bezin J, Gouverneur A, Penichon M, Mathieu C, Garrel R, Hillaire-Buys D, Pariente A, Faillie JL. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2023. PMID: 36356111.
  6. 6.Kindel TL, Wang AY, Wadhwa A, Schulman AR, Sharaiha RZ, Kroh M, Ghanem OM, Levy S, Joshi GP, LaMasters TL; American Gastroenterological Association; American Society for Metabolic and Bariatric Surgery; American Society of Anesthesiologists; International Society of Perioperative Care of Patients with Obesity; Society of American Gastrointestinal and Endoscopic Surgeons. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Obes Relat Dis. 2024. PMID: 39482213.
  7. 7.U.S. Food and Drug Administration. FOUNDAYO (orforglipron) tablets — Section 4 Contraindications; Section 8.1 Pregnancy (may cause fetal harm; discontinue when pregnancy is recognized); Section 12.3 Elimination. SetID 8ac446c5-feba-474f-a103-23facb9b5c62. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  8. 8.U.S. Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications — Drug Safety Communication, January 13, 2026. Meta-analysis of 91 placebo-controlled trials in 107,910 patients found no increased risk; Saxenda, Wegovy, and Zepbound labeling updated in February 2026. FDA Drug Safety. 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp

Foundayo (Orforglipron) Side Effects: Comprehensive Evidence Review

Comprehensive Foundayo (orforglipron) adverse-event review across the three pivotal trials: ATTAIN-1 in obesity, ATTAIN-2 in T2D, and ATTAIN-MAINTAIN switch-and-maintain. GI dominance, dose discontinuations, class warnings, and head-to-head AE comparison with Wegovy and Zepbound.

14 min read

Retatrutide vs Foundayo (orforglipron) — TRIUMPH-1 vs ATTAIN-1 cross-trial evidence

Retatrutide −25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs Foundayo (orforglipron) ~−11% at 17.2 mg / 72 wk (ATTAIN-1), roughly 2.2× on a cross-trial basis. Both are Eli Lilly molecules; Foundayo is FDA-approved (April 2026), retatrutide is investigational.

12 min read

Foundayo (Orforglipron) Week-by-Week (2026): Days 1-90 Titration Schedule, What to Expect & Common Questions

Foundayo moves up at least every 30 days: 0.8, 2.5, 5.5, 9, 14.5, then 17.2 mg. This days 1-90 guide covers the label's side effect rates at the top dose (nausea 35%, vomiting 24%, diarrhea 25%) and what the 72-week ATTAIN trials showed.

12 min read

GLP-1 Pills (2026): Rybelsus, Foundayo & the New Wegovy Tablet — Side-by-Side Comparison of Every Oral GLP-1

Three oral GLP-1 pills are FDA-approved: Rybelsus (type 2 diabetes only), Foundayo (orforglipron, for weight since April 2026) and Wegovy tablets (since December 2025). All are once daily, but food rules, indications and effect sizes differ.

13 min read

Switching Between Foundayo (Orforglipron) and Zepbound (Tirzepatide): What the FDA Labels Say About Dose Equivalence (2026)

There is no mg-for-mg conversion between Foundayo and Zepbound, and neither FDA label provides an equivalence table, so switching is a prescriber decision. Cross-trial weight loss at 72 weeks was 11.1% on Foundayo 17.2 mg versus 20.9% on Zepbound 15 mg.

11 min read

What Is Orforglipron (Foundayo)? Mechanism, Maker & Pronunciation

Orforglipron (Foundayo) is Eli Lilly's once-daily oral GLP-1, the first non-peptide GLP-1 approved for weight loss, cleared by the FDA on April 1, 2026. Being a small molecule is why it can be a pill. How it works, ATTAIN-1 results, and how to pronounce it.

10 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Read full review →

Pricing Compare

Get started →
8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

Pricing Compare

Get started →
7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

Pricing Compare

Get started →